135 related articles for article (PubMed ID: 10169387)
1. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.
Chancellor JV; Hill AM; Sabin CA; Simpson KN; Youle M
Pharmacoeconomics; 1997 Jul; 12(1):54-66. PubMed ID: 10169387
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
Mauskopf J; Lacey L; Kempel A; Simpson K
Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
[TBL] [Abstract][Full Text] [Related]
3. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
[TBL] [Abstract][Full Text] [Related]
5. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
6. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
Staszewski S; Hill AM; Bartlett J; Eron JJ; Katlama C; Johnson J; Sawyer W; McDade H
AIDS; 1997 Mar; 11(4):477-83. PubMed ID: 9084795
[TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
[TBL] [Abstract][Full Text] [Related]
8. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
Kuritzkes DR; Quinn JB; Benoit SL; Shugarts DL; Griffin A; Bakhtiari M; Poticha D; Eron JJ; Fallon MA; Rubin M
AIDS; 1996 Aug; 10(9):975-81. PubMed ID: 8853730
[TBL] [Abstract][Full Text] [Related]
10. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
11. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
[TBL] [Abstract][Full Text] [Related]
13. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Martínez E; Ribera E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Larrousse M; Curran A; Negredo E; Arterburn S; Ferrer P; Álvarez ML
HIV Med; 2015 Jul; 16(6):370-4. PubMed ID: 25496141
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
16. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord
Eur J Clin Pharmacol; 2017 Apr; 73(4):463-468. PubMed ID: 28028587
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Ruiz L; Romeu J; Martínez-Picado J; Schmit JC; Vandamme AM; Balagué M; Cabrera C; Puig T; Tural C; Segura A; Sirera G; De Clercq E; Clotet B
AIDS; 1996 Dec; 10(14):F61-6. PubMed ID: 8970679
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.
Lacey L; Hopkinson PK; Montaner J; Leblanc F; Gill MJ
Pharmacoeconomics; 1999; 15 Suppl 1():55-66. PubMed ID: 10537442
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
